Compare QNST & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QNST | MGTX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.8M | 1.1B |
| IPO Year | 2009 | 2018 |
| Metric | QNST | MGTX |
|---|---|---|
| Price | $15.49 | $11.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $24.75 | $24.57 |
| AVG Volume (30 Days) | 666.4K | ★ 688.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $282,140,000.00 | $81,391,000.00 |
| Revenue This Year | $18.59 | $141.38 |
| Revenue Next Year | $14.80 | N/A |
| P/E Ratio | $14.47 | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $10.29 | $6.62 |
| 52 Week High | $18.02 | $15.35 |
| Indicator | QNST | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 47.40 |
| Support Level | $13.68 | $8.84 |
| Resistance Level | $16.32 | $11.85 |
| Average True Range (ATR) | 0.68 | 0.59 |
| MACD | -0.27 | -0.19 |
| Stochastic Oscillator | 13.27 | 28.08 |
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia. Geographically, it operates in United States and Internationally, of which maximum revenue is derived from United States.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.